Norvir 400% Price Hike Gets Appeals Court OK; Abbott Can Thank AT&T
Drug firms should have fewer antitrust worries when making formulation and pricing changes for their products based on a recent appeals court decision
You may also be interested in...
Safeway, Walgreens, Kroger, New Albertson's and American Sales Company file an antitrust complaint against Abbott Oct. 26 claiming that its 400 percent Norvir price hike in 2003 restricted competition in the market for protease inhibitor boosters. Abbott increased the wholesale price of Norvir from $205.74 to $1,028.71 but did not increase the price of its Kaletra, which incorporates Norvir. The price hike drastically increased the price of competing regimens using Norvir to boost PIs, the complaint says, forcing plaintiffs to pay higher prices. The Prescription Access Litigation filed a similar class action antitrust suit against Abbott in 2004...
The agency's "Bad Ad" program issued a warning letter that claims the promotion for CooperSurgical's copper-containing intrauterine contraceptive lacked any safety information.
During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.